TCGA-39-5040-01A-21R-2125-07
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.450
- E2F_TARGETS+0.440
- MITOTIC_SPINDLE+0.430
- MYC_TARGETS_V2+0.350
- MYC_TARGETS_V1+0.340
- TGF_BETA_SIGNALING+0.250
- UV_RESPONSE_DN+0.220
- UNFOLDED_PROTEIN_RESPONSE+0.190
- ANDROGEN_RESPONSE+0.140
- PROTEIN_SECRETION+0.140
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.420
- ALLOGRAFT_REJECTION-0.400
- INFLAMMATORY_RESPONSE-0.360
- INTERFERON_GAMMA_RESPONSE-0.350
- KRAS_SIGNALING_UP-0.340
- FATTY_ACID_METABOLISM-0.330
- PANCREAS_BETA_CELLS-0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
- HEDGEHOG_SIGNALING-0.300
- NOTCH_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AQ-A04H-01B-11R-A10J-07 | — | B | 0.857 |
| 2 | 62b39052-bdb9-4ba6-9eb0-f117480c98a8 | — | — | 0.842 |
| 3 | TCGA-63-A5MH-01A-12R-A27Q-07 | — | cohortSQ1 | 0.837 |
| 4 | TCGA-AR-A0TZ-01A-12R-A084-07 | — | B | 0.836 |
| 5 | TCGA-A2-A0T3-01A-21R-A115-07 | — | B | 0.834 |
| 6 | TCGA-43-6143-01A-11R-1820-07 | — | cohortMD1 | 0.829 |
| 7 | MDT-AP-0167 | Med | Medulloblastoma | 0.824 |
| 8 | MDT-AP-3297 | Med | Medulloblastoma | 0.824 |
| 9 | TCGA-78-7155-01A-11R-2039-07 | — | cohortMD1 | 0.822 |
| 10 | MDT-AP-0138 | Med | Medulloblastoma | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.010 | Inavolisib | — uncovered |